Topographical resolution of jaw movements mediated by cyclase- vs. non-cyclase-coupled dopamine D1-like receptors: Studies with SK&F 83822

European Journal of Pharmacology

Volumn 538, Issue 1-3, 2006, Pages 94-100

  Fujita, Satoshi ^a   Lee, Jun ^a   Kiguchi, Motori ^a   Uchida, Takuya ^a   Cools, Alexander R ^b   Waddington, John L ^c   Koshikawa, Noriaki ^a  

^a NIHON UNIVERSITY   (Japan)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

(Rat); Cyclase coupled; Dopamine D1 like receptor; Dopamine D1 like:D2 like receptor interaction; Jaw movement; Non cyclase coupled; Orofacial movement; SK F 83822; SK F 83959

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; 6 CHLORO 7,8 DIHYDROXY 3 ALLYL 1 [3 METHYLPHENYL] 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADENYLATE CYCLASE; BENZAZEPINE DERIVATIVE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; EMONAPRIDE; PHOSPHATIDYLINOSITIDE; QUINPIROLE; SKF 83822; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; HYDROLYSIS; JAW MOVEMENT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; TONGUE; TOPOGRAPHY;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; 2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ADENYLATE CYCLASE; ANALYSIS OF VARIANCE; ANIMALS; BENZAMIDES; BENZAZEPINES; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; JAW; MALE; MOVEMENT; QUINPIROLE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; TIME FACTORS;

EID: 33646500775     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.03.056     Document Type: Article

References (34)

1. 2-like receptor synergism. Eur. J. Pharmacol. 367 (1999) 143-149
2. 1-like receptors. Eur. J. Pharmacol. 473 (2003) 47-54
3. 1 receptor efficacy. Eur. J. Pharmacol. 188 (1990) 335-347
4. 1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine. Eur. J. Pharmacol. 334 (1997) 141-147
5. 1-like receptors in the prefrontal cortex and nucleus accumbens: a key to its antiparkinsonian effect in animals?. Neuropharmacology 42 (2002) 237-245
6. 1-like receptors in jaw movements. Eur. J. Pharmacol. 423 (2001) 171-178
7. 1 dopamine receptors in rat brain. J. Neurochem. 85 (2003) 378-386
8. Koshikawa N., Tomiyama K., Omiya K., and Kobayashi M. Ketamine anaesthesia has no effect on striatal dopamine metabolism in rats. Brain Res. 444 (1988) 394-396
9. Koshikawa N., Aoki S., Hiruta M., Tomiyama K., Kobayashi M., Tsuboi Y., Iwata K., Sumino R., and Stephenson J.D. Effects of intrastriatal injections of selective dopamine D-1 and D-2 agonists and antagonists on jaw movements of rats. Eur. J. Pharmacol. 163 (1989) 227-236
10. 2 receptors in rat jaw movements. Eur. J. Pharmacol. 201 (1991) 47-51
11. Lee J., Adachi K., Gionhaku N., Fujita S., Uchida T., and Koshikawa N. Measurement of dopamine receptor-mediated jaw movements by a magnet-sensing system in freely moving rats. Methods Find. Exp. Clin. Pharmacol. 25 (2003) 525-530
12. 1 dopamine receptor interacting protein. Science 287 (2000) 1660-1664
13. 2+ mobilization in Xenopus oocytes. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 2196-2200
14. 2-like interactions: cautionary observations on SK&F 82958 as an anomalous agent. J. Psychopharmacol. 18 (2004) 484-495
15. 1A dopamine receptor mutants: ethologically based resolution of behavioural topography indicates genetic background as a determinant of knockout phenotype. Neuropsychopharmacology 28 (2003) 86-99
16. 1A receptor-deficient mice. Synapse 39 (2001) 319-322
17. Murray A.M., and Waddington J.L. The induction of grooming and vacuous chewing by a series of selective D-1 dopamine receptor agonists: two directions of D-1:D-2 interaction. Eur. J. Pharmacol. 160 (1989) 377-384
18. 1-like dopamine receptors: molecular biology and pharmacology. In: Di Chiara G. (Ed). Handbook of Experimental Pharmacology: Dopamine in the CNS (2002), Springer, Heidelberg 122-158
19. 1-like receptors: behavioural topography. Eur. J. Pharmacol. 486 (2004) 273-280
20. 2-like interactions. Synapse 55 (2005) 201-211
21. 1-like interactions. Synapse 59 (2006) 107-118
22. 35)S]GTP(S binding and phosphoinositide hydrolysis in rat and monkey brain. Neuropharmacology 40 (2001) 826-837
23. 1 receptor actions. Biol. Psychiatry 50 (2001) 501-509
24. 2-like receptor regulation. Eur. J. Pharmacol. 418 (2001) 47-54
25. 1A receptor 'knockout' mice. Neuropharmacology 42 (2002) 644-652
26. 3 receptor "knockout". Synapse 51 (2004) 71-81
27. 1 receptor enhances inositol phosphate formation in rat brain. J. Pharmacol. Exp. Ther. 253 (1990) 987-992
28. 1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain. J. Neurochem. 62 (1994) 2045-2048
29. Undie A.S., Berki A.C., and Beardsley K. Dopaminergic behaviors and signal transduction mediated through adenylate cyclase and phospholipase C pathways. Neuropharmacology 39 (2000) 75-87
30. 2 dopaminergic function. Adv. Exp. Med. Biol. 204 (1986) 125-136
31. 2-like dopamine receptor systems. In: Niznik H.B. (Ed). Dopamine Receptors and Transporters: Pharmacology, Structure and Function (1994), Marcel-Dekker, New York, NY 511-537
32. 2-like" receptors. Prog. Neuro-psychopharmacol. Biol. Psychiatry 19 (1995) 811-831
33. Waddington J.L., Clifford J.J., McNamara F.N., Tomiyama K., Koshikawa N., and Croke D.T. The psychopharmacology-molecular biology interface: exploring the behavioural roles of dopamine receptor subtypes using targeted gene deletion ['knockout']. Prog. Neuro-psychopharmacol. Biol. Psychiatry 25 (2001) 925-964
34. Waddington J.L., O'tuathaigh C., O'sullivan G., Tomiyama K., Koshikawa N., and Croke D.T. Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface. Psychopharmacology 181 (2005) 611-638